Skip to main content
LGNZZ logo

Ligand Pharmaceuticals, Inc. (LGNZZ) Stock Price & Analysis

Ligand Pharmaceuticals, Inc. (LGNZZ) — price $0.065 (0.00%), as of the Nov 18, 2026 trading session; market cap $1.40M.

Educational signal · not a buy or sell recommendation · How to read this

$0.065 $0.00 (0.00%) Market Cap $1.40M

Ligand Pharmaceuticals, Inc. · LGNZZ

Ligand Pharmaceuticals, Inc. is a global biopharmaceutical company focused on advancing and licensing pharmaceutical assets, leveraging its Captisol platform to enhance drug formulations. The firm operates a royalty-based business model through strategic partnerships with major pharmaceutical entities, addressing diverse critical health conditions.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.065
Change on the day0.00%
52-week range$0.06 – $0.17
Market capitalisation$1.40M
Price / earnings (trailing)113.44
Shares traded on the day150

Price & events

Other perspectives

Council score for Ligand Pharmaceuticals (LGNZZ): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ligand Pharmaceuticals (LGNZZ), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ligand Pharmaceuticals, Inc. (LGNZZ) is the company analyzed here. It employs 47 people and is led by Todd C. Davis. In Q3 FY2026 it reported revenue of $79M and net income of -$28M. The market values it at $1.40M.

2 · Latest results

What do the latest results show for Ligand Pharmaceuticals (LGNZZ)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $79M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$79M-$28M-$1.43 (diluted)
Q2 FY2026$64M$49M$2.22 (diluted)
Q1 FY2026$52M-$13M-$0.67 (diluted)
Q4 FY2025$60M$45M$2.12 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ligand Pharmaceuticals (LGNZZ)?

Short answer

The distress and quality screens read Altman Z 0.59 · Piotroski F 4. Trailing ratios: ROE 5.4% · ROA 1.2% · current ratio 1.22.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LGNZZ in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LGNZZ in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Ligand Pharmaceuticals Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the LGNZZ research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is LGNZZ a good stock to buy?

Stock Expert AI does not rate LGNZZ buy, sell or hold. Ligand Pharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LGNZZ stock price today?

The last price recorded for Ligand Pharmaceuticals, Inc. (LGNZZ), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does Ligand Pharmaceuticals, Inc. navigate regulatory approval processes?

As a biopharmaceutical firm operating in a highly regulated industry, Ligand Pharmaceuticals, Inc. navigates regulatory approval processes primarily through its strategic partners.

What are the key factors to evaluate for LGNZZ?

Evaluate LGNZZ on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. New partnerships could lead to royalties from blockbuster drugs in various therapeutic areas over the long term. Not financial advice.

How frequently does LGNZZ data refresh on this page?

LGNZZ's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LGNZZ's recent stock price performance?

Ligand Pharmaceuticals, Inc. (LGNZZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Captisol platform enhances drug formulations, a key technological asset. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LGNZZ overvalued or undervalued right now?

The trailing P/E of Ligand Pharmaceuticals, Inc. (LGNZZ) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research LGNZZ before investing?

Before investing in Ligand Pharmaceuticals, Inc. (LGNZZ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.